Thymalfasin powder

Structure of Thymalfasin

What is Thymalfasin raw powder?

Thymalfasin raw powder, also known as thymosin-alpha 1, is an immune system modulator with the ability to enhance Thl immune responses. Researchers evaluated its immunomodulatory functions and potential for treating a variety of diseases. These diseases include cancer, AIDS, chronic hepatitis B and C, primary immunodeficiency diseases, and suppressed vaccination responses. In these conditions, Thymalfasin has been shown to improve many immune system parameters and increase T cell differentiation and maturation. ^[1]Therefore, its main role is to modulate immune reactivity. Thymalfasin is responsible for rebuilding the immune system when thymus tissue is reinfused into thymectomized animals. Thymalfasin has also been shown to be effective in experimental models of immune dysfunction.^[2][3]

Thymalfasin, also known as Zadaxin, is a 28-amino acid synthetic peptide that is a synthetic version of thymosin alpha 1. Thymosin alpha 1 is a naturally occurring substance in the human thymus and circulatory system. It is formulated as an injection for subcutaneous administration. Used in multiple indications such as chronic hepatitis B, cancer adjuvants, vaccine boosters, and immune boosters. It is used to vaccinate immunocompromised people against influenza.

Thymalfasin has been developed to treat sepsis, solid tumors, thymoma, thymic carcinoma, and acute pneumonia. Additionally, it is being developed for the treatment of non-small cell lung cancer and advanced metastatic malignant melanoma (US).^[15]

Thymalfasin’s mechanism of action

Thymalfasin’s mechanism of action is unclear. But it is thought to affect the immune system, primarily by enhancing the function of T cells. Thymosin α1 has been shown to promote T cell differentiation and maturation. For example, increases in CD4+, CD8+, and CD3+ cells have all been shown to be normal. Thymosin alpha 1 has also been shown to increase IL-2 receptor expression, increase NK cell activity, increase migration inhibitory factor (MIF) production, increase antibody responses to T cell-dependent antigens, and upon mitogen or antigen activation Then increase the expression of IL-2 receptor. In addition, thymosin α1 was shown to induce dexamethasone leading to thymocyte apoptosis. Administration of thymosin α1 in animals whose immune systems have been suppressed by chemotherapy, tumor burden, or radiation has been shown to prevent bone marrow cytotoxic damage, tumor progression, and possible infection, thereby extending survival time and the number of survivors. Thymosin α1 achieves many of its functions in vitro and in vivo by promoting the differentiation of pluripotent stem cells into thymocytes or activation into activated T cells. ^[4][5]In vitro studies have also shown that thymosin can upregulate the expression of Toll-like receptors (TLRs), including TLR2 and TLR9, as well as the NF-kB and JNK/P38/AP1 pathways in mouse and human dendritic cells.

Thymalfasin Benefits

Thymalfasin and chronic hepatitis B

Thymalfasin is used for chronic hepatitis B, as monotherapy or with interferon. A pooled analysis of 3 randomized controlled trials with 223 patients was performed. Thymosin alpha 1 twice a week for six months. ^[6][8]Follow-up assessments were conducted 12 months after the end of treatment (see table). Multiple studies have shown that treatment response to ZADAXIN (thymofacine) is delayed 12 months or more after completion of treatment. While taking thyfaxin (ZADAXIN), transient increases in ALT to more than twice the baseline value (flare) may occur. When ALT is elevated, ZADAXIN (thymofaxine) should generally be continued unless the following signs and symptoms occur: Hepatic failure.

Thymalfasin and chronic hepatitis C

ZADAXIN thymalfasin (thymosin alpha 1) is used with interferon to treat chronic hepatitis C. A comprehensive analysis of 121 patients treated with ZADAXIN (thymosin) or interferon was conducted, including 2 randomized controlled trials and 1 historical controlled trial. Thymosin alpha 1 at least twice weekly for 6 to 12 months; interferon up to 3 times weekly. Follow-up assessments were conducted at the end of treatment and six months after the end of treatment (see table).^[7][9]

A pooled intention-to-treat analysis showed that among patients who received combination therapy, the sustained biochemical (ALT) response, defined as normal ALT 6 to 12 months after completion of treatment, was 22.4%; among patients who received interferon alone, the ALT response was 9.3 %.

Thymalfasin and cancer

ZADAXIN thymalfasin (thymosin alpha 1) is indicated for the adjuvant treatment of non-small cell lung cancer (NSCLC), malignant melanoma, hepatocellular carcinoma (HCC), breast cancer, chemotherapy-induced immunosuppression, immune insufficiency, and  immunosuppression. Non-Hodgkin lymphoma (CHOP program), colorectal cancer, head and neck cancer, leukemia, pancreatic cancer, and renal cell carcinoma. According to clinical studies of more than 1,000 patients with various cancers, thymosin alpha 1 improves immunological parameters, improves tumor response rates, and improves survival and quality of life (see table for some studies). Treatment cycles with thymosin alpha 1 are 6 months or between chemotherapy.^[10]

Thymalfasin and HCV

Hepatitis C virus (HCV) is the most common indication for liver transplantation and a leading cause of cirrhosis and hepatocellular carcinoma. The World Health Organization estimates that 170 million people worldwide are infected with HCV. According to a recent national survey of 20,288 participants, nearly 4 million people are infected with HCV in the United States alone (3) and 864,000 Mexicans are infected.

Most patients infected with HCV genotype 1 and with high viral loads do not achieve sustained remission. Among patients with genotype 1 who did not respond to the first 12 weeks of IFN alpha-2a and ribavirin, only 12% achieved sustained remission after treatment with PEG IFN alpha-2a plus ribavirin. Additionally, race can affect treatment outcomes; for example, African-American and Hispanic patients respond the worst to treatment. The likelihood of achieving SVR is further reduced by the need to suspend treatment due to adverse events.

Thymalfasin has recently shown success in treating chronic hepatitis C virus infection. Thymalfasin is a peptide composed of 28 amino acids, which can promote the activity of NK cells, increase the proliferation of lymphocytes CD3, CD4 and CD8, and stimulate interferon alpha, interferon gamma and IL2. In addition, it has a direct antiviral effect , by increasing the expression of class I major histocompatibility complex (MHC) molecules and reducing viral replication.

Thymalfasin and COVID-19 infection

Thymalfasin is a naturally occurring peptide that has been studied for its immunomodulatory activity and ability to treat a variety of diseases and conditions, including cancer and infectious diseases. Thymalfasin, a synthetic version produced under the brand name ZADAXIN, is currently approved for use in 37 countries. In China, it is approved to treat hepatitis B and enhance vaccine response.^[13][14] In clinical trials, Thymalfasin has been used to treat severe acute respiratory syndrome (SARS) and other lung infections such as acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease, chronic obstructive pulmonary disease, and subsequent bone marrow transplantation Infect. 

A recent study conducted a retrospective analysis of hospitalized COVID-19 patients in China. After treatment with Thymalfasin, the patient’s condition improved and mortality among lymphocyte subsets significantly decreased (from 30% to 11%, p = 0.04).

Post-marketing treatment experience with Thymalfasin demonstrates that it is well tolerated in more than 600,000 patients. Thymalfasin is used in the elderly (age over 101 years), children (as young as 13 months), and immunocompromised patients. Injection site pain (eg, burning and soreness) was the most common adverse event (AE) reported in past clinical trials. Itching) symptoms are mild and last less than 30 minutes, along with fever, nausea, and flu-like symptoms that are mild to moderate in severity. Thymalfasin is one of the few immune modulators approved for use in humans, but it does not appear to cause most of the side effects and toxicities associated with other biological response modifiers (BRMs), such as interferons and interleukin (IL)-2.

Thymalfasin and melanoma

Based on recent understanding of the complex pathophysiology of melanoma and severe sepsis, immunomodulatory substances such as thymosin α1 (INN: thymosin; abbreviated Ta1) may be useful in treating these two unrelated immunosuppressive indications.

In the lung metastasis model, treatment with Ta1 alone reduced metastasis by 32% (p < 0.05). Furthermore, the combination of Ta1 and anti-PD-1 antibodies resulted in relatively minor metastases. The tumor growth model showed a significant decrease in Ta1 dose, from 34% (p = 0.015) to 46% (p = 0.001). Ta1 treatment showed positive trends toward improved survival and reduced bacterial load in CLP sepsis models. Ta1 appears to have an effect on the levels of certain biomarkers in CLP models as well.

All three models showed benefit after Ta1 treatment, with no evidence of toxicity. These early pilot studies support the idea that immunosuppressive indications such as sepsis and melanoma can be treated with Ta1 alone or in combination with other immunosuppressive therapies.

How to make Thymalfasin inhaled powder spray

1. The preparation of the auxiliary materials, including the carrier box additive

Accessories: including sugar, amino acids, and polyol alcohols of one or two or more mixtures

Additives: Including one or two or more mixtures in one or two or more mixtures in the surfactant, lubricant, and anti -static additives

2. Preparation method:

• Take the THYMALFASIN through micro -powder and get the thymalfasin ultra -micro powder
• Crush the auxiliary materials
• Take the thymus method new ultra -micro powder and the auxiliary materials prepared by Step 2 and shatter it. Mix it according to the incremental method and use the appropriate capsule to pack.

Thymalfasin Dose

Administration and Dosage

ZADAXIN (Thymalfasin) is administered subcutaneously and should not be administered intravenously. Before use, 1.0 ml of diluent (consisting of 1.0 ml of sterile water for injection) should be reconstituted immediately before use. Doctors can instruct patients to self-administer medications as needed.

Persistent hepatitis B

The recommended dose of ZADAXIN (Thymalfasin) is 1.6 mg (900 g/m2) subcutaneously administered twice weekly for the treatment of chronic hepatitis B (per interferon label dosage and schedule). The duration of treatment ranges from 6 to 12 months. For patients weighing less than 40 kg, 40 g/kg of ZADAXIN (Thymalfasin) should be administered.

Cancer

The recommended dose of thymusfacine (Thymalfasin) for the treatment of cancer is 1.6 mg (900 g/m2), administered subcutaneously for 6 months, or between chemotherapy cycles.

About providing

Each vial of ZADAXIN (Thymalfasin) contains 1.6 mg of lyophilized thymosin alpha 1. Each box contains two vials of ZADAXIN (Thymalfasin). Additionally, each carton contains two ampoules of ZADAXIN diluent, each ampoule containing 1.0 ml of sterile water for injection for reconstitution of ZADAXIN.

Store

Store thymofaxine (ZADAXIN) between 2° to 8°C (36° to 46° F). Remade ZADAXIN should be taken immediately.

Thymalfasin powder Side Effects

At typical doses (less than 3 mg), there are no significant or systemic adverse effects. In the phase I study, 2.4 mg/m 2 was administered intramuscularly to patients with advanced cancer. The only adverse reaction was fever, which occurred in only 1 out of 4 users; in addition, 4.8 or 9.6 mg/m 2 was administered. When the dose was administered to 6 patients, 2 of them experienced mild nausea.

Raw Thymalfasin powder For Sale |Thymalfasin powder supplier

Thymalfasin is a thymic hormone. It mainly exerts immunomodulatory effects by enhancing T cell activity. It can be used alone or with interferons as an immunomodulator to treat chronic hepatitis B and C. In addition, it has shown certain therapeutic effects during the new coronavirus epidemic. Studies have shown that Thymalfasin can effectively treat some cancers. Its therapeutic functions have attracted widespread attention.

Researchers interested in experimenting with Thymalfasin powder will want to ensure that they source this material from a reliable supplier. lf you’re looking to buying Thymalfasin powder online, it is essential to exercise caution and ensure that you obtain the peptide from a reputable and trustworthy manufacuturer. Polypeptide.Ltd is a highly reliable manufacturer that offers pharmaceutical grade peptides.